NPGS offers a good alternative to trabeculectomy

Article

Non-penetrating glaucoma surgery (NPGS) is a safe and effective filtering procedure and could offer an alternative to trabeculectomy in patients with open angle glaucoma, according to Dr Aslan and colleagues from Ege University School of Medicine, Turkey.

Non-penetrating glaucoma surgery (NPGS) is a safe and effective filtering procedure and could offer an alternative to trabeculectomy in patients with open angle glaucoma, according to Dr Aslan and colleagues from Ege University School of Medicine, Turkey.

A total of 112 patients (124 eyes) with uncontrolled primary and secondary open angle glaucoma, were enrolled to take part in the study. The patients were divided into four treatment groups: viscocanalostomy (56 eyes), deep sclerectomy with non-absorbable T-Flux implant (33 eyes), deep sclerectomy with reticulated hyaluronic acid implant (SKGEL) (14 eyes) and deep sclerectomy with collagen implant (DSCI).

Mean intraocular pressure (IOP) decreased from 25.5±7.6 mmHg at baseline to 15.9±4.6 mmHg at six months, to 17.0±5.6 mmHg at one year, 16.7±4.1 mmHg at year three and 15.5±2.5 mmHg at year five in all patients. No significant difference in success rate was found between the various techniques.

The investigators suggest that NPGS is not only safe and effective, but may be a good alternative to trabeculectomy in patients with uncontrolled open angle glaucoma.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.